MTA1 and prostate carcinoma: Although there is much work yet to be done to reveal the full potential of Gnetin C, substantial information already exists to justify the evaluation of Gnetin C in chemoprevention/interception prostate cancer clinical trials, in which only those patients under active surveillance with MTA1 overexpression are recruited.